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Background: Matrix metalloproteases and collagen are key participants in breast cancer, but their precise roles in
cancer etiology and progression remain unclear. MMP13 helps regulate collagen structure and has been ascribed
largely harmful roles in cancer, but some studies demonstrate that MMP13 may also protect against tumor
pathology. Other studies indicate that collagen’s organizational patterns at the breast tumor-host interface influence
metastatic potential. Therefore we investigated how MMP13 modulates collagen I, a principal collagen subtype in
breast tissue, and affects tumor pathology and metastasis in a mouse model of breast cancer.
Methods: Tumors were implanted into murine mammary tissues, and their growth analyzed in Wildtype and
MMP13 KO mice. Following extraction, tumors were analyzed for collagen I levels and collagen I macro- and
micro-structural properties at the tumor-host boundary using immunocytochemistry and two-photon and second
harmonic generation microscopy. Lungs were analyzed for metastases counts, to correlate collagen I changes with
a clinically significant functional parameter. Statistical analyses were performed by t-test, analysis of variance, or
Wilcoxon-Mann–Whitney tests as appropriate.
Results: We found that genetic ablation of host stromal MMP13 led to: 1. Increased mammary tumor collagen I
content, 2. Marked changes in collagen I spatial organization, and 3. Altered collagen I microstructure at the
tumor-host boundary, as well as 4. Increased metastasis from the primary mammary tumor to lungs.
Conclusions: These results implicate host MMP13 as a key regulator of collagen I structure and metastasis in
mammary tumors, thus making it an attractive potential therapeutic target by which we might alter metastatic
potential, one of the chief determinants of clinical outcome in breast cancer. In addition to identifying stromal
MMP13 is an important regulator of the tumor microenvironment and metastasis, these results also suggest that
stromal MMP13 may protect against breast cancer pathology under some conditions, a finding with important
implications for development of chemotherapies directed against matrix metalloproteases.
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The structure and function of tumor extracellular matrix
(ECM) play critical roles in cancer initiation and
outcome [1,2]. More specifically, organization or
reorganization of collagen, a key structural component
of the ECM, has been shown to be an important factor
in tumor genesis, progression, and/or metastasis [3-9].
Tumor cells have been shown to migrate preferentially
along aligned collagen fibers [10,11], and others have
reported particular “tumor associated collagen signa-
tures” (TACS) – i.e. patterns of collagen alignment
around the tumor boundary – that may be associated
with breast cancer tumor invasion into host stroma [5]
and patient survival [12]. However specific functional
mechanisms or molecular mediators that lead to such
collagen reorganizations, with consequent effects on
tumor progression and metastasis, remain largely un-
defined and would represent attractive novel therapeutic
targets for breast cancer.
Some likely mediators of collagen structure at the
tumor-host interface are matrix metalloproteases (MMPs).
MMPs are key regulators of the ECM and collagen remod-
eling [13,14], and are also frequently implicated in cancer
[15]. MMP-13 (collagenase-3) was originally isolated from
human breast cancer tissue [16], and has been shown to
be an important contributor to breast (and other) cancer
pathology [15,17,18]. As a collagenase with fairly broad
substrate specificity, MMP-13 is capable of cleaving sev-
eral collagen subtypes including fibrillar collagens I, II,
and III [15]. These fibrillar collagens are detectable by
second harmonic generation (SHG) microscopy, an op-
tical imaging approach that is increasingly being used
to provide diagnostic insights into cancer biology [9],
and which has been used extensively in TACS analysis
[5,12,19]. Collagen I is the most abundant fibrillar col-
lagen in mammals [20], is a substrate for MMP-13 [15],
and is typically increased in breast tumor- versus nor-
mal mammary gland-associated stroma [21,22]. Finally,
Col1a1 transgenic mice with degradation resistant col-
lagen I have been used for TACS analysis of increased
collagen deposition in a mammary tumor model [19].
Therefore, in this study we sought to determine
whether direct in vivo genetic manipulation of host
MMP-13 alters collagen I organization at the mammary
tumor-host boundary (i.e. TACS), with demonstrable
effects on tumor metastasis.
Methods
Cells and reagents
Murine medullary mammary adenocarcinoma (E0771)
cells syngeneic with C57BL/6 mice (Roswell Park Cancer
Institute, Buffalo, NY) were grown in RPMI 1640
medium (Gibco/Invitrogen, Carlsbad, CA) supplemented
with 10% gamma-irradiated defined fetal bovine serum(HyClone/Thermo-Fisher, Waltham, MA) and 100 ug/
ml Primocin antibiotic (InvivoGen, San Diego, CA). For
mammary tumor implantation experiments, cells were
harvested in 0.25% trypsin/EDTA, centrifuged, re-
suspended in sterile PBS, and kept on ice until implant-
ation into a mammary fat pad.
Tumor implantation
Congenic female C57BL/6 wildtype (WT) or MMP-13
knockout (MMP13 KO) mice [23] were used for E0771
tumor implantation experiments at 15–19 weeks of age.
Animals were anesthetized with ketamine/xylazine (90/9
mg/kg) delivered intraperitoneally (i.p.). The animals’
ventral surfaces were depilated, followed by implantation
of 1×105 E0771 mammary tumor cells into the right in-
guinal mammary fat pads using a 27-gauge needle.
Caliper-measured tumor sizes were recorded on days 12,
19, and 28 of the experiments. On Day 28 post-
implantation, animals were sacrificed by i.p. sodium
pentobarbital injection and subsequent cervical disloca-
tion. The E0771 mammary tumors were excised, and
immediately snap-frozen on dry ice for subsequent cryo-
sectioning and immunohistochemistry. Lungs were ex-
cised, fixed in 10% neutral-buffered formalin, then paraffin
embedded, sectioned, and hematoxylin-eosin (H&E)
stained for analysis of lung metastases. Procedures were
performed in accordance with the University Committee
on Animal Resources (UCAR).
Immunohistochemistry
Snap-frozen tumors were cryo-sectioned (−21°C) at 20
um, then static-mounted on positively charged slides. For
immunohistochemistry (IHC), sections were cold-fixed
(−20°C) for 20 minutes in 3:1 acetone/methanol,
rehydrated 2 × 5 minutes in sterile PBS, then blocked for
one hour (5% BSA, .2% Triton-X 100 in PBS). Primary
antibody for Collagen I (Abcam #21286, Cambridge, MA)
was then applied for 2 hours at room temperature in a hu-
midified chamber, diluted 1:200 in 0.5% BSA, .2% Triton-
X 100 in PBS, followed by 2 × 5 minutes PBS wash, then
two hours of Alexa Fluor 594-conjugated goat anti-rabbit
IgG (1:500 in the same diluent as the primary; Invitrogen,
Carlsbad, CA). Optimal antibody dilutions and incubation
times were pre-determined empirically. Following staining
for Collagen I protein, tumor sections were washed and
mounted in ProLong Gold Antifade reagent (without
DAPI; Invitrogen, Carlsbad, CA), then allowed to dry for
24 hours before imaging. Similar procedures were used for
IHC against MMP-13 (Millipore #ab8120, Billerica, MA).
Imaging and image analysis
Slides were imaged by a blinded observer using a
custom-built multi-photon microscope. A Mai Tai Ti-
tanium:sapphire laser (Newport/Spectra Physics, Santa
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pulses at 80 MHz and 810 nm) for simultaneously
epidetecting backwards-directed SHG (BSHG) and im-
munofluorescence (IF) signals from Collagen I fibers in
the excised mammary tumors. Beam scanning and image
acquisition were performed with a custom-modified
Fluoview FV300 confocal scanner interfaced with a
BX61WI upright microscope (Olympus, Center Valley,
PA), with an Olympus XLUMPLFL20xW water immer-
sion lens (20×, 0.95 N.A.). Backscattered SHG (HQ405/
30m-2P emission filter, Chroma, Rockingham, VT;
HC125-02 PMT, Hamamatsu Corporation, Hamamatsu,
Japan) and 2P-excited Collagen I IF (Chroma HQ635/30
m-2P emission filter; HC125-01 Hamamatsu PMT) sig-
nals were separated from the 810 nm excitation beam by
a short pass dichroic mirror (Chroma 670 DCSX), and
simultaneously captured in two distinct channels (using
a 475 DCSX Chroma long pass dichroic, and the emis-
sion filters and PMTs above) on every scan. Resulting two-
channel (BSHG and IF) images are 680 microns across.
Laser power was monitored and kept constant throughout
each experiment and across experimental repetitions, as
were PMT voltage, gain, and offset.
Because MMP13 was knocked out from the host ani-
mal, for the results described herein we analyzed images
representing random tumor-host interface regions, i.e.
random “outer edge” regions of tumors. Images from
these areas were obtained as z-stacks (1 um step size)
taken over the entire 20 um thickness of the tissue sec-
tion. For each channel (BSHG and collagen I IF), max-
imum projection images were taken from each stack,
then image analysis was performed with ImageJ as fol-
lows. For each slide (usually 2–3 tumor sections/slide)
and for each channel, background was defined by the
average pixel counts of a laser-excited image taken from
an area of the slide with no tissue, and subtracted from
the raw BSHG and IF images. These background correc-
ted images were used for image analysis in ImageJ. For
assessment of collagen I protein levels, mean pixel inten-
sity of collagen I IF was measured over the tumor per-
iphery FOVs. For coherency analysis, the coherency
parameter (see below, and [24-26]) was calculated on
these same collagen I IF images using the ImageJ plugin
OrientationJ (open source, written by Daniel Sage, Bio-
medical Image Group, EPFL, Switzerland; http://
bigwww.epfl.ch/demo/orientation/). This coherency par-
ameter was quantified on a pixel-by-pixel basis, then av-
eraged over all pixels in an image to produce a single
coherency value for each image, which could then be av-
eraged across all images in each experimental group. For
normalized SHG calculations (i.e. BSHG normalized to
collagen I IF), the BSHG and collagen I IF images were
thresholded to select for collagen I-positive features
and to reduce artifactual effects from non-specificbackground in either channel, applying the same
thresholding standard to images from all experimental
groups. The BSHG channel was then “masked” to the
thresholded collagen I IF channel, so that only SHG
pixels that were also positive for collagen I immunofluor-
escence were analyzed. Dividing the mean BSHG pixel in-
tensity from these masked BSHG images, by the mean IF
pixel intensity from the corresponding Collagen I IF im-
ages from the same FOV, produces a ratiometric value
which represents BSHG normalized to Collagen I protein
levels on a pixel-by-pixel basis over the exact same XYZ
pixel space, for each tumor periphery image. This
method of analysis allows us to analyze only the BSHG
signal that is primarily restricted to collagen I, and pro-
vides a “normalized” BSHG value for collagen I. Since
SHG is sensitive to both collagen microstructural prop-
erties and collagen abundance [9,27], this “normalized”
BSHG parameter allows us to primarily assess changes in
collagen I microstructural properties with reduced sensi-
tivity to changes in collagen I expression levels, and
similar strategies have been employed by others previ-
ously [28,29]. To calculate the forward SHG (FSHG) to
BSHG ratio (FSHG/BSHG), both FSHG and BSHG were cap-
tured simultaneously above (BSHG) and below (FSHG) the
slide specimen in two channels using the microscope
setup previously described [30]. FSHG and BSHG images
were simultaneously collected as stacks of 11 images
spaced 3μm apart, within a 660 μm field of view. Four
images were taken from each tumor sample around the
tumor boundary at the tumor-host interface, with 2
tumor samples analyzed per animal from the same co-
horts of WT and MMP13 KO animals. Image analysis
was conducted with ImageJ. Each stack was maximum
intensity projected, serving as an “autofocus” for the ef-
fectively single layer of collagen. Projected images were
background subtracted using a maximum intensity pro-
jection of a matching 11 image scan taken with a closed
shutter, then background subtracted FSHG and BSHG im-
ages were divided to create an FSHG/BSHG ratio image.
For each image a common threshold was applied to all
images to distinguish collagen pixels from background
pixels and to select for fibers likely to be collagen I, and
subthreshold background (i.e. non collagen fiber) pixels
were excluded from analysis by binary masking. The
average pixel value these non-background collagen fiber
pixels was calculated from all FSHG/BSHG ratio images in
the same cohort of MMP13 KO and WT animals, and
expressed as mean FSHG/BSHG ± SEM.
Evaluation of lung metastases
For evaluation of lung metastases, lungs were excised
from tumor bearing experimental animals as described
above, fixed in 10% neutral-buffered formalin, then par-






















Figure 1 Host MMP13 knockout does not alter mammary
tumor size. E0771 mouse mammary tumor cells were implanted
into the mammary fat pad of congenic female C57BL/6 WT or
MMP13 KO mice as described in Methods. Tumors were measured
with calipers at days 12, 19, and 28 post-implantation, and tumor
volume calculated. There was no difference in tumor volume
between WT and MMP13 KO mice at any of the time points,
indicating that MMP13 knockout does not alter E0771 mouse
mammary tumor size. Plot represents mean tumor volumes ± SEM
from a cohort of WT (blue) (n=6) and MMP13 KO (red) (n=4) mice.
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positively charged slides, then H&E stained. H&E-
stained lung sections were evaluated for lung metastases
by a trained blinded observer using brightfield micros-
copy (Olympus BX-51, Center Valley, PA). Metastatic in-
filtrating tumor cells were identified by several criteria
including: high ratio of hematoxylin relative to eosin,
surrounding abnormalities in lung structure, abnormal
shape/size of nuclei and/or presence of abnormal mitotic
spindles, and differences in cell shape and size, with ≥ 1
infiltrating tumor cells counted as a metastatic event.
Results are presented as mean number of lung metasta-
ses/cm2 ± SEM for each treatment group.
Statistical analysis
Statistical analysis was performed using Kaleidagraph
(Synergy Software, Reading, PA) or Prism 5 (GraphPad
Software, La Jolla, CA) software. Student’s t-tests (un-
paired), ANOVA with protected Fisher LSD post-tests
for planned comparisons, or Wilcoxon-Mann–Whitney
tests were used for statistical analyses as appropriate.
p-values ≤ .05 were considered significant.
Results
Stromal MMP13 knockout increases mammary tumor
Collagen I content, but decreases Collagen I ordering, at
the tumor-host interface
Murine medullary breast adenocarinoma (E0771) tumor
cells were implanted into mouse mammary fat pads for
28 days. Consistent with other reports [31], MMP13 KO
did not alter mammary tumor size in our E0771 mam-
mary tumor model (Figure 1). MMP-13 expression was
decreased in tumors from the MMP13 KO mice versus
WT (Additional file 1: Figure S1A) and moreover, in the
WT but not MMP13 KO mice, MMP13+ cell bodies
were found around the tumor periphery which suggested
the presence of peritumor (and possibly infiltrating)
MMP13+ stromal cells in WT but not MMP13 KO mice
(compare Additional file 1: Figures S1B and S1C, re-
spectively). Also at the tumor periphery, Collagen I pro-
tein levels were significantly increased in MMP13 KO
versus wildtype animals as quantified by immunofluores-
cence staining (Figure 2), suggesting that depletion of
this collagen degrading enzyme from host cells increases
tumor Collagen I content. However, despite this increase
in Collagen I content at the tumor boundaries in the
MMP13 KO mice, overall collagen ordering at tumor
boundaries was decreased (i.e. more random) in these
MMP13 KO mice versus WT controls. Figure 3 high-
lights the decreased ordering in MMP13 KO mice, with
WT mice demonstrating many robust Collagen I fibers
more frequently oriented parallel to the tumor boundary,
closely resembling a TACS-2 arrangement as previously
described [5,12,19] (Figure 3A). Compared to these WTmice, MMP13 KO mice in contrast, although they had
greater overall collagen I content (Figure 1), displayed
fewer robust linear collagen I fibers, and a more ran-
domly oriented collagen I distribution closely resembling
a TACS-1 arrangement (Figure 3B). In adjacent sections
of the same WT tumor as shown in Figure 3A, antibody
labeling for MMP13 around the tumor periphery appeared
to be closely localized with the robust TACS-2 patterned
Collagen I fibers oriented parallel to the tumor boundary
(Additional file 2: Figure S2), thus further implicating
MMP-13 as likely to be a key orchestrator of these ob-
served TACS changes in Collagen I organization.
To quantify these differences in local orientations of
collagen I fibers, we performed tensor analysis of local
image structure to calculate the coherency parameter
(C), which is the ratio of the difference and sum of the
largest (λmax) and smallest (λmin) tensor eigenvalues
(averaged for all pixels over the image FOV), as follows:
C ¼ λmax−λminð Þ= λmax þ λminð Þ ð1Þ
With the upper bound C = 1 indicating highly ori-
ented structures, and the lower bound C = 0 indicating
high isotropy [24-26]. This analysis clearly indicated that
Collagen I in mammary tumor peripheries of WT mice























Figure 2 MMP13 knockout increases Collagen I levels in E0771
mammary tumors. WT and MMP13 KO mice were implanted with
E0771 mammary tumors as described. Following excision of the primary
tumor, tumor boundary regions were assessed for Collagen I levels by
immunochemistry. Immunofluorescence signal was captured by two-
photon excitation microscropy of fields of view (FOV) from random
tumor boundary regions. Z-stacks from each FOV were maximum
intensity projected and background subtracted, and fluorescent
intensities from the resultant images were quantified with ImageJ and
then expressed as mean anti-Collagen I immunofluorescence ± SEM
from n=16 (WT) and n=14 (MMP13 KO) tumor FOVs from the same
cohort of animals. Collagen I levels in tumor peripheries were
significantly increased in MMP13 KO versus WT mice (*p < .0004).
Figure 3 MMP13 knockout decreases Collagen I ordering at E0771 m
implanted with E0771 mammary tumors as described. Following excision a
assessed for Collagen I spatial organization by qualitative (this figure) and q
immunofluorescence signal. Images of Collagen I signal were taken as desc
more organized and ordered Collagen I structure, characterized in particula
tumor boundary, compared to MMP13 KO mice (Panel B) which demonst
like Collagen I fibers.
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mice (less ordered, C closer to 0) (Figure 4). Figure 5 shows
a pseudo-colored map of these coherency values using the
same images as in Figure 3 (more visible bright red areas =
higher coherency).
Together these results suggest that depletion of host
(stromal) MMP13 – a key collagen degrading enzyme –
increased total collagen I content, but reduced collagen I
organization, in the periphery of E0771 mammary tu-
mors grown in MMP13 KO versus WT mice.
Stromal MMP13 knockout alters Collagen I microstructure
at the tumor-host interface
SHG results when two photons (e.g. as provided by the
near-IR titanium sapphire laser in a multiphoton mi-
croscope), interacting simultaneously with a non-
centrosymmetric target such as collagen fibers, combine
to produce a new photon with exactly twice the energy
and half the wavelength of the interacting photons
[9,32-36]. As a coherent phenomenon, SHG is intrinsic-
ally sensitive to spacing and regularity of scatterers, and
hence can be utilized to detect changes in several as-
pects of collagen microstructure including regularity of
the arrangement of collagen fibrils within larger collagen
fibers; interfibril spacing; and fibril diameter, tilt angle,
or pitch angle [4,7,9,27,34,37-41]. Collagen I is a particu-
larly strong SHG emitter in vivo [7], is a substrate for
MMP13 [15], is increased in breast cancer stroma
[21,22], and is an important contributor to TACS [19].
Figures 2, 3, 4 and 5 assessed collagen I macrostructural
properties (i.e. gross fiber orientations and arrangement)ammary tumor boundaries. WT and MMP13 KO mice were
nd sectioning of the primary tumor, tumor boundary regions were
uantitative (next figure) analysis of anti-Collagen I
ribed in Figure 2. Note that WT mice (Panel A) exhibited a much
r by longer and thicker Collagen I fibers oriented more parallel to the
































Figure 4 Quantifying decreased Collagen I ordering at the
E0771 mammary tumor boundary in MMP13 KO mice. WT and
MMP13 KO mice were implanted with E0771 mammary tumors as
described, and images of anti-Collagen I immunofluorescence
staining at the tumor-host interface were obtained as described in
Figure 3. As described in Methods and Results, to quantitatively
assess Collagen I ordering we calculated the mean coherency
parameter averaged over all pixels in each image, thus producing a
single coherency value for each image. This coherency value for
each image was averaged for n=16 (WT) and n=14 (MMP13 KO)
tumor boundary FOV images (± SEM) from the same cohort of
animals to produce this plot. Mean coherency was significantly
decreased in the MMP13 KO versus WT mice (*p < .007), reflecting
less organized (more randomly oriented) collagen I structure.
Coherency values for each image were produced using OrientationJ
(http://bigwww.epfl.ch/demo/orientation/), then graphed in
Kaleidagraph (Synergy Software, Reading, PA).
Figure 5 Coherency maps of decreased Collagen I ordering at the E07
representative images as in Figure 3 were combined with their respective p
Hue-Saturation-Brightness (HSB) images (H = Constant; S = Coherency; B =
reflects greater coherency. Compare more bright red signal signifying grea
coherency in MMP13 KO (Panel B). Coherency maps were produced using
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ings, we now wished to analyze collagen I microstruc-
tural properties at the tumor-host interface as assessed
by SHG. For these reasons, we restricted our SHG ana-
lysis to the intensity of SHG signals emanating primarily
from collagen I fibers, specifically using the “normalized
BSHG” as described in Methods to provide an SHG
measure of collagen I microstructural properties inde-
pendent of changes in collagen I protein levels, as well
as to gain particular insight into changes in the effective
diameter or packing arrangement/density of fibrils
within the SHG focal volume [4,27,30,34,42].
Figures 3, 4 and 5 demonstrated that while tumors in
both WT and MMP13 KO mice contained both “diffuse”
and “large fiber” patterns of collagen I, there was propor-
tionately more “diffuse” collagen I with apparently thin-
ner fiber structure or bundling on average in MMP13
KO tumors, versus proportionately more “large fiber”
collagen I in WT tumors (often ordered parallel to the
tumor boundary resembling a TACS-2 signature, e.g.
Figure 3A). Therefore we hypothesized that knockout of
MMP13 collagenase activity could cause differences in
collagen I micro-structural properties – e.g. regularity or
density of collagen fibrils within larger collagen fibers; fi-
bril spacing; and fibril diameter, tilt angle, or pitch angle
[4,7,9,27,34,37-41] – which might in turn account for
the different collagen I macrostructural phenotypes ob-
served in MMP13 KO versus WT mice.
As described here and in Methods, we measured colla-
gen I-normalized BSHG in the same WT and MMP13
KO animals and tumor-host interface regions as
depicted in Figures 1, 2, 3, 4 and 5. We found that nor-
malized BSHG was significantly higher in the E077171 mammary tumor boundary in MMP13 KO mice. The same
ixel-by-pixel coherency maps (calculated as described for Figure 4) as
Original Image), such that increased amounts of “bright red” signal
ter coherency in WT (Panel A), versus less bright red signal and lesser
Orientation J (http://bigwww.epfl.ch/demo/orientation/).
Perry et al. BMC Cancer 2013, 13:411 Page 7 of 12
http://www.biomedcentral.com/1471-2407/13/411tumor peripheries of MMP13 KO versus WT mice
(Figure 6A), suggesting different collagen I microstruc-
ture between these two groups [28,29]. To validate and
complement these findings, we also measured the FSHG/
BSHG ratio in these same groups and tumor-host inter-
face regions. SHG is emitted both forwards (away from
the incoming laser) and backwards (back towards the in-
coming laser, i.e. epi-directed) from the SHG-generating
scatterers in the focal volume, and the FSHG/BSHG ratio
is an additional SHG parameter that is primarily sensi-
tive to the spatial extent of SHG-generating scatterers
along the optical axis, i.e. the effective diameter or pack-
ing arrangement/density of collagen fibrils within the
SHG focal volume [4,27,30,34,42]. We found this FSHG/
BSHG ratio was significantly decreased in the E0771
tumor peripheries of MMP13 KO versus WT mice
(Figure 6B). Together these two pieces of data suggest
collagen I microstructure is altered in MMP13 KO
versus WT mice, which may in turn relate to the ob-
served changes in collagen I macrostructure (e.g. dif-
ferences in average fiber density, apparent thickness,
and organization) seen in Figures 3, 4 and 5.
Together these results suggest that stromal host
MMP13 depletion alters both collagen I macrostructural
(i.e. fiber arrangement, ordering, and orientation; Figures 2,
3, 4 and 5), and molecular (fibril) microstructural proper-
ties (as quantified by collagen I normalized BSHG and
FSHG/BSHG; Figure 6) at the tumor periphery. Since WT
tumor peripheries showed significantly more robust “rodFigure 6 MMP13 knockout alters Collagen I microstructure at the tum
E0771 mammary tumors. (A) Following excision of the primary tumor, tum
immunofluorescence and BSHG signal were captured simultaneously in sep
fields of view (FOV) from random tumor boundary regions. Z-stacks from e
subtracted, SHG and collagen I immunofluorescence signals masked to the
(i.e. BSHG normalized to collagen I levels) was calculated as mean BSHG pixe
images over the same XYZ pixels. This ratiometric normalized collagen I SH
from the same cohort of animals, and was higher in MMP13 KO versus WT
we also calculated FSHG/BSHG values, which provides insight into microstruc
and/or packing density/arrangement of collagen fibrils. FSHG/BSHG was sign
WT mice (p < .01).like” collagen I fibers (often in a more TACS-2-like orien-
tation), compared to the higher proportion of “diffuse” fi-
bers in MMP13 KO animals (often in a more TACS-1-like
orientation) (Figure 3), these results further suggest the
possibility that MMP13 KO changes collagen I micro-
structure in ways that 1. Could alter collagen’s ability to
form and orient larger, more rod-like fibers, and/or 2. May
shift the relative balance between “diffuse” and “rod-like”
collagen I phenotypes.
Stromal MMP13 knockout increases mammary tumor
metastasis to lung
Collagen is a key component of the extracellular matrix
(ECM) which regulates cell behavior and motility
[1,8,10,43], metastasizing breast tumor cells in particular
have shown a propensity to “escape” the tumor by trav-
eling along collagen fibers [5], and particular collagen
patterns or “TACS” at the breast tumor periphery are as-
sociated with poor survival [12]. Therefore the observed
collagen I macro- and micro-structural changes at the
tumor-host interface might be expected to affect tumor
metastasis.
For these reasons, and because breast tumor metasta-
sis to lung is associated with poor prognosis [44], we
wished to determine whether the changes in collagen I
macro- and micro-structural properties demonstrated
above could be associated with changes in this clinically
significant parameter. Indeed, we found that along with
their differing collagen I macro- and micro-structuralor-host interface. WT and MMP13 KO mice were implanted with
or boundary regions were labeled with anti-collagen I. Collagen I
arate epidetection channels by two-photon excitation microscopy of
ach FOV were maximum intensity projected and background
same pixel areas, then from these masked images “normalized BSHG”
l value/mean collagen I immunofluorescence pixel value ± SEM for all
G value was calculated for 16 (WT) and 14 (MMP13 KO) tumor FOVs
tumor boundaries (p < .03). (B) From the same cohort of animals,
tural collagen changes, specifically the sub-resolution diameter
ificantly decreased in tumor boundary regions of MMP13 KO versus
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imals also had roughly double the number lung metasta-
ses compared to WT animals (Figure 7). This difference
in metastasis was not due simply to differences in tumor
burden between the WT and MMP13 KO animals, as
tumor burden was unchanged (Figure 1).
Discussion
The ECM, and collagen in particular, are increasingly be-
lieved to play important roles in cancer etiogenesis, pro-
gression, and outcome [1-9]. Several previous reports
have demonstrated that tumor cells may preferentially
travel along collagen fibers [10,11], which may represent
an important pathway by which invading cells
metastasize [5,11]. Accordingly, collagen fibers oriented
perpendicularly to the tumor boundary in what has been
termed a “TACS-3” configuration, have been associated
with increased invasiveness into host stroma [5] and
with decreased patient survival [9,12]. In contrast,
TACS-2 collagen configuration- i.e. straight “taut” fibers
often parallel to the tumor boundary-was associated with
regions of decreased tumor invasiveness [5].
MMPs have been implicated in many cancers includ-
ing breast cancer, most likely due to their ability to
modulate this collagen- and ECM-rich extracellular en-
vironment [45]. While a majority of studies have found
pro-tumorigenic roles for most MMPs, a growing body
of literature suggests that some or even many MMPs
may have anti-cancer effects as well [46,47]. Protective
effects of MMPs against tumor pathology may in part
account for the relative failure of MMP inhibitors as ef-
fective chemotherapeutics [46,48,49], and this concept is
further supported by evidence that endogenous tissue in-
hibitors of matrix metalloproteinases (TIMPs) can them-
selves be cancer-promoters [50-53]. MMP13 inFigure 7 MMP13 knockout increases mammary tumor metastasis to l
mammary fat pad of congenic female C57BL/6 WT or MMP13 KO mice as d
and processed for H&E staining for analysis of metastases. Representative im
metastastic burden (see arrows indicating metastases) in the MMP13 KO gr
equidistant sampling step sections through both lobes of the lung per ani
demonstrating that MMP13 KO mice had nearly double the number of lunparticular has widely been found to promote cancer
pathology, but a few emerging reports including this one
find an apparently protective role for MMP13 in cancer
and other diseases under some conditions [54,55]. More-
over, there remains limited understanding of exactly how
MMP-13 interactions with collagen impact tumor path-
ology – for example, what structural changes result from
these interactions, and how do these changes promote
or protect against tumor pathology? In the studies de-
scribed here, we have provided further insights into
these important questions.
Herein we extended this previous work by demonstrat-
ing that in vivo genetic ablation of host MMP-13 in a
mouse tumor model leads to altered collagen I
macro- and micro-structure at the tumor-host inter-
face, and increases mammary tumor metastasis to the
lungs, a clinically significant functional outcome measure.
This represents a direct experimental manipulation of
the TACS stage of the tumor and therefore implicates
stromal MMP13 as one driver of TACS evolution in
breast tumors. These results are important because they
help clarify the role of host MMP13 in tumor collagen
dynamics, breast cancer pathogenesis, and metastasis.
They are also important because this is one of few stud-
ies that have found a potentially protective effect for
host MMP13 in the context of cancer pathology, and it
is important to understand these intricacies of MMP13’s
roles in cancer biology – i.e. when, where, and how it
may have protective versus deleterious functions in
cancer – in order to develop effective, targeted MMP-
based therapies that do more good than harm.
Due to the fact that tumor cells migrate preferentially
along aligned collagen fibers [10,11], our findings of de-
creased metastasis (Figure 7) associated with collagen I
TACS-2 patterning (i.e. fibers parallel to the tumorung. E0771 mouse mammary tumor cells were implanted into the
escribed in Methods. At day 28 post-implantation, lungs were excised
ages from the (A) WT and (B) MMP13 KO animals show increased
oup. (C) Metastases/cm2 were counted and averaged from 10
mal from a cohort of WT (n=6) and MMP13 KO (n=4) mice,
g metastases compared to their WT counterparts (*p < .006).
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studies demonstrating decreased tumor invasiveness also
in TACS-2 areas [5], together support the hypothesis
that alignment of collagen fibers parallel to the tumor
boundary may effectively serve as a literal “barrier” or
“diversion” to metastasizing tumor cells. Continuing this
argument, it is easily seen how the contrasting TACS-3
pattern found in the literature, i.e. collagen fibers ori-
ented perpendicular to the tumor boundary, may allow
metastasizing cells to travel outward along these colla-
gen “tracks” to more readily invade the host [5,10].
While we did not find significant TACS-3 patterning in
our model system, our data suggest that the TACS-1
patterning (i.e. increased, more diffuse collagen depos-
ition) resulting from knockout of stromal MMP13 may
also result in increased metastasis if present in late-stage
tumors, we posit because it is far less “barrier like” than
TACS-2 patterning (e.g. compare Figures 3A and 3B, re-
spectively), thus allowing for relatively easier escape of
metastasizing tumor cells, possibly due to less diversion
of those cells onto paths parallel to the tumor boundary.
In these previous reports, TACS-1 patterns were not
investigated in detail for metastases effects, because in
their model the TACS-1 collagen pattern tended to
occur early in tumor formation before significant metas-
tases occurred [5]. TACS-1 is characterized by dense,
more diffuse collagen areas [5], consistent with the in-
creased collagen I seen in the TACS-1 MMP13 KO
group (Figure 2), which likely results from the absence
of this key collagen I-degrading collagenase. Moreover,
while E0771 tumor cells appear to have some level of
MMP13 expression (Additional file 1: Figure S1 and
unpublished data), as is common in mammary tumor
cells [56-58], we believe most significant for our find-
ings are the more strongly MMP13+ peritumor cell
bodies seen in MMP13 expressing WT animals, but not
in the MMP13 KO mice (compare Additional file 1:
Figures S1B and S1C respectively, and unpublished
data). These MMP13+ cell bodies found around the
tumor periphery in WT but not MMP13 KO mice sug-
gest the presence of peritumor (and possibly infiltrating)
MMP13+ stromal cells which may contribute to the al-
tered TACS patterns and metastases observed in WT
versus MMP13 KO mice. These results, together with
our finding that MMP13+ staining appears localized
with the “barrier-like” Collagen I fibers around the tumor
periphery in the TACS-2 (WT) condition (Additional file 2:
Figure S2), all suggest that MMP13 in particular may be a
principal contributor to TACS phenotype. The fact that
MMP13 KO results in TACS-1 collagen patterning similar
to what others have seen in “early stage” tumors in their
mammary tumor models [5] suggests that the lack of
MMP13 prevents the tumor stroma from progressing to a
“late stage” structure. This is supported by the literatureobservation that MMP13 can be a critical mediator of
“early stage” tumor events [59].
In addition to these macrostructural collagen I
changes, which we posit may impact tumor cells’ inva-
sive potential, we also found changes in collagen I micro-
structure as measured by SHG. As described above and
previously, SHG is sensitive to changes in collagen
microstructure including regularity of collagen fibrils
within larger collagen fibers; fibril compaction; and fibril
diameter, tilt angle, or pitch angle [4,7,9,27,34,37-41],
and therefore SHG signal normalized to collagen I levels
can provide a quantitative measure of collagen I micro-
structure which is less dependent on changes in collagen
I protein levels. Furthermore, typically as the diameter of
collagen fibrils or small fibers (i.e. small bundles of fi-
brils) increases, their SHG becomes more forward-
directed, and thus the FSHG/BSHG ratio also increases
[42]. Therefore our findings of lower collagen I BSHG
(Figure 6A), and higher FSHG/BSHG (Figure 6B), in WT
versus MMP KO mice is seemingly consistent with our
observations of generally more large rod-like collagen I
fibers in WT mice, versus apparently thinner and more
diffuse collagen I fibers on average in MMP13 KO mice
(Figures 3, 4 and 5). These findings also introduce the
possibility that changes in collagen I microstructure (as
measured by SHG) may alter collagen I’s ability to form
larger rod-like fibers, thus altering the relative propor-
tions of “diffuse” versus “large fiber” collagen I (and
TACS patterning) in WT versus MMP13 KO mice
(Figures 3, 4 and 5).
In further support of our work here, another report
using mouse mammary tumor virus polyoma middle T
(MMTV-PyMT) mice crossed with MMP13 KO mice,
noted proportionately more “thin collagen fibers” (rela-
tive to total collagen) in tumors from MMP13 KO com-
pared to WT mice as assessed by picrosirius red staining
under linearly polarized light [31], although in this study
additional macro- or micro-structural collagen changes,
and collagen I in particular, were not investigated. Our
data here suggest further that collagen I may be a princi-
pal contributor to these MMP13-regulated changes in
collagen architecture and organization, at least in some
mammary tumor models.
This hypothesis that changes in collagen I microstruc-
tural properties (measurable by SHG) may in turn contrib-
ute to observable changes in collagen I macrostructure
requires further investigation in future studies beyond the
scope of this report, but we can propose at least several
ways by which this might occur. Regulation of collagen I
fibril formation, fiber length and thickness, and
organization is exceedingly complex and may involve nu-
merous cellular and biochemical interactions with colla-
gen I, just a few of which include protease activity
by many MMPs, proteoglycan interactions, and/or
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associated collagen subtypes or other ECM molecules
[20,60,61]. Notably, there are several mechanisms by
which MMP-13 in particular could induce collagen I
microstructural changes, which further manifest them-
selves as macrostructural changes in collagen I fiber diam-
eter. First, MMP-13 cleaves the collagen I amino terminal
non-helical telopeptide end [62], which in turn promotes
lateral fiber growth whereas leaving this site intact de-
creases lateral growth and is associated with initial forma-
tion of thin fibrils [63,64] – thus providing robust support
for our results that WT mice (i.e. with normal MMP-13
cleavage of this site) show thicker fibers, whereas
MMP13-KO mice (lacking MMP-13 cleavage of this site)
have proportionately more thin (diffuse) fibers. Moreover,
MMP-13 has been shown to degrade decorin [65], a pro-
teoglycan known to be a key regulator of collagen I fiber
diameter [66]. Further supporting our results, less decorin
(i.e. more MMP-13) has typically been associated with
thicker collagen I fibers [67,68], as we saw in the WT
mice. Finally, MMP-13 can degrade collagen III which
may result in altered fiber-diameter regulating interactions
between collagen I and collagen III [69], or between colla-
gen I and amino-terminal propeptide of type III
procollagen which is thought to interact with Collagen I
to regulate fiber diameter [70,71].
Conclusions
In this work we have directly shifted a mouse model of
breast cancer from one TACS state to another by knock-
out of stromal MMP13, implicating stromal MMP13 as
one driver of TACS state. This also altered the meta-
static output in a manner consistent with the TACS lit-
erature, although the relationship between TACS and
metastatic output is not necessarily causal based upon
our data. This suggests that pharmacological manipula-
tion of MMP13 activity is an attractive avenue of explor-
ation in order to manipulate TACS state and hence
attempt to alter metastatic output. In total, these novel
findings that MMP13 may have beneficial roles in cancer
biology by significantly altering collagen I dynamics and
metastatic potential, help to further clarify MMP13’s po-
tentially protective roles in tumor pathology and thus fa-
cilitate future design of more specifically targeted and
effective MMP-based therapies that minimize risks to
the patient.
Additional files
Additional file 1: Figure S1. Decreased MMP13 expression in MMP13
KO tumors. WT and MMP13 KO mice were implanted with E0771
mammary tumors as described. (A) Following excision of the primary
tumor, MMP13 gene expression was assessed by quantitative PCR (qPCR)
and normalized to 1, showing decreased MMP13 expression in MMP13KO versus WT tumors (p < .03) in the same cohort of WT (n=6) and
MMP13 KO (n=4) mice. In addition, following immunofluorescence
labeling for MMP13, the tumors from the (B) WT mice had peritumor
MMP13+ cell bodies which were not apparent in the tumors from the
(C) MMP13 KO mice. To assure details are visible for illustrative purposes,
the original grayscale MMP13 immunofluorescence is shown with
“Green” LUT applied in ImageJ, with levels (screen stretch) linear and set
the same for both images.
Additional file 2: Figure S2. MMP13 at the tumor periphery is
patterned like Collagen I in TACS-2. MMP13 immunofluorescence of
adjacent sections of the same WT tumor as depicted in Figures 3A and
5A illustrates that MMP13 protein expression appears to align with the
TACS-2 patterned Collagen I fibers depicted in Figures 3A and 5A, which
are robust and oriented in a “barrier like” fashion around the tumor
periphery, as is the MMP13 labeling shown here. Fiber banding patterns
are visible amidst the MMP13 fluorescence labeling in this image. For
illustrative purposes, the original grayscale MMP13 immunofluorescence
is shown with a spectral lookup table (“Fire” LUT in ImageJ) applied and
linear screen stretch (levels) set to assure details are visible for qualitative
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